(Total Views: 316)
Posted On: 12/17/2019 7:26:31 AM
Post# of 154466
Re: Cytodynamite #12833
What is for you an operational success for a clinical stage biotech?
Isnt it about good study results, and moving forward to commercialisation?
How would you rate the success in these areas for CYDY?
How many Biotechs on Nasdaq have actually revenues? If you would be right, more than half of them would not be listed. Most of them are way behind the development of CYDY. And we not even talked yet about the potential we have, which is unique. And yet, most of them can raise money so much easier and on better terms.
Despite that, you missed the part where I stated that there are other options for uplisting which dont need an R/S.
There are firms specialised in helping with that.
Reversed merger with some shell company is just one example.
Isnt it about good study results, and moving forward to commercialisation?
How would you rate the success in these areas for CYDY?
How many Biotechs on Nasdaq have actually revenues? If you would be right, more than half of them would not be listed. Most of them are way behind the development of CYDY. And we not even talked yet about the potential we have, which is unique. And yet, most of them can raise money so much easier and on better terms.
Despite that, you missed the part where I stated that there are other options for uplisting which dont need an R/S.
There are firms specialised in helping with that.
Reversed merger with some shell company is just one example.
(0)
(0)
